Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Belite Bio, Inc before investing.

In this article, we go over a few key elements for understanding Belite Bio, Inc’s stock price such as:

• Belite Bio, Inc’s current stock price and volume
• Why Belite Bio, Inc’s stock price changed recently
• Upgrades and downgrades for BLTE from analysts
• BLTE’s stock price momentum as measured by its relative strength

About Belite Bio, Inc (BLTE)

Before we jump into Belite Bio, Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Want to learn more about Belite Bio, Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Belite Bio, Inc.

Belite Bio, Inc’s Stock Price as of Market Close

As of May 13, 2026, 9:46 AM, CST, Belite Bio, Inc’s stock price was $158.500.

Belite Bio, Inc is up 1.9% from its previous closing price of $155.540.

During the last market session, Belite Bio, Inc’s stock traded between $150.000 and $158.500. Currently, there are approximately 36.22 million shares outstanding for Belite Bio, Inc.

Belite Bio, Inc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Belite Bio, Inc Stock Price History

Belite Bio, Inc’s (BLTE) price is currently down 0.41% so far this month.

During the month of May, Belite Bio, Inc’s stock price has reached a high of $160.240 and a low of $147.840.

Over the last year, Belite Bio, Inc has hit prices as high as $200.000 and as low as $56.100. Year to date, Belite Bio, Inc’s stock is down 0.91%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Belite Bio, Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 12, 2026, there were 0 analysts who downgraded Belite Bio, Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Belite Bio, Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Belite Bio, Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Belite Bio, Inc (BLTE) by visiting AAII Stock Evaluator.

Relative Price Strength of Belite Bio, Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 12, 2026, Belite Bio, Inc has a weighted four-quarter relative price strength of 14.42%, which translates to a Momentum Score of 85 and is considered to be Very Strong.

Want to learn more about how Belite Bio, Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Belite Bio, Inc Stock Price: Bottom Line

As of May 13, 2026, Belite Bio, Inc’s stock price is $158.500, which is up 1.9% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Belite Bio, Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.